When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. That said, here are three stocks where the outlook is warranted and some alternatives with better fundamentals.
Teradyne (TER)
Consensus Price Target: $449.80 (1.3% implied return)
Sporting most major chip manufacturers as its customers, Teradyne (NASDAQ:TER) is a US-based supplier of automated test equipment for semiconductors as well as other technologies and devices.
Why Is TER Not Exciting?
- Products and services resonate with customers, evidenced by its respectable 5.3% annualized sales growth over the last five years
- Estimated sales growth of 24.4% for the next 12 months implies demand will slow from its two-year trend
- Free cash flow margin shrank by 6.2 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
Teradyne is trading at $443.97 per share, or 42.9x forward P/E. Read our free research report to see why you should think twice about including TER in your portfolio.
Lennar (LEN)
Consensus Price Target: $86.23 (-0.4% implied return)
One of the largest homebuilders in America, Lennar (NYSE:LEN) is known for constructing affordable, move-up, and retirement homes across a range of markets and communities.
Why Do We Think LEN Will Underperform?
- Demand cratered as it couldn’t win new orders over the past two years, leading to an average 9.2% decline in its backlog
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 8.9% annually while its revenue grew
- Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability
At $86.54 per share, Lennar trades at 15.4x forward P/E. If you’re considering LEN for your portfolio, see our FREE research report to learn more.
Henry Schein (HSIC)
Consensus Price Target: $97.56 (9.9% implied return)
With a vast inventory of over 300,000 products stocked in distribution centers spanning more than 5.3 million square feet worldwide, Henry Schein (NASDAQ:HSIC) is a global distributor of healthcare products and services primarily to dental practices, medical offices, and other healthcare facilities.
Why Are We Hesitant About HSIC?
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Earnings growth underperformed the sector average over the last five years as its EPS grew by just 3.9% annually
- Diminishing returns on capital suggest its earlier profit pools are drying up
Henry Schein’s stock price of $88.78 implies a valuation ratio of 15.9x forward P/E. Check out our free in-depth research report to learn more about why HSIC doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.